BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Van den Berghe N, Gils A, Thomas D. Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted? Clin Pharmacol Ther 2019;106:945-54. [PMID: 31420861 DOI: 10.1002/cpt.1609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
2 Simsek M, Deben DS, Horjus CS, Bénard MV, Lissenberg-Witte BI, Buiter HJC, van Luin M, Seinen ML, Mulder CJJ, Wong DR, de Boer NKH, van Bodegraven AA. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Aliment Pharmacol Ther 2019;50:54-65. [PMID: 31094013 DOI: 10.1111/apt.15280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
3 Becker HEF, Penders J, Jonkers DMAE. Microbial Metabolism of Inflammatory Bowel Disease Drugs: Current Evidence and Clinical Implementations. Gastroenterology 2021:S0016-5085(21)03488-0. [PMID: 34508777 DOI: 10.1053/j.gastro.2021.07.050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ter Horst P, Smolders EJ, den Besten-Bertholee D. Mercaptopurine and Metabolites in Breast Milk. Breastfeed Med 2020;15:277-9. [PMID: 31414890 DOI: 10.1089/bfm.2019.0101] [Reference Citation Analysis]
5 Al-Ani AH, Prentice RE, Rentsch CA, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae FA, Ng SC, Rubin DT, Christensen B. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther 2020;52:54-72. [PMID: 32348598 DOI: 10.1111/apt.15779] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 20.0] [Reference Citation Analysis]
6 Di Paolo A, Luci G. Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Front Pharmacol 2020;11:610806. [PMID: 33628180 DOI: 10.3389/fphar.2020.610806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Skrzypczak-Zielinska M, Gabryel M, Marszalek D, Dobrowolska A, Slomski R. NGS study of glucocorticoid response genes in inflammatory bowel disease patients. Arch Med Sci 2021;17:417-33. [PMID: 33747278 DOI: 10.5114/aoms.2019.84470] [Reference Citation Analysis]
8 de Hoogd S, Wong DR, de Vries DR, Harmsze AM. Severe pancytopenia and aspergillosis caused by thioguanine in a thiopurine S-methyltransferase deficient patient: a case report. Eur J Gastroenterol Hepatol 2019;31:1592-6. [PMID: 31464791 DOI: 10.1097/MEG.0000000000001504] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]